新型四氢吡啶并[3,4-]嘧啶类化合物作为用于治疗癌症、炎症和自身免疫性疾病的HPK1抑制剂
Novel Tetrahydropyrido[3,4-]pyrimidines as HPK1 Inhibitors for Treating Cancer, Inflammatory, and Autoimmune Diseases.
作者信息
Sabnis Ram W
机构信息
Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States.
出版信息
ACS Med Chem Lett. 2024 Jan 31;15(3):318-319. doi: 10.1021/acsmedchemlett.4c00023. eCollection 2024 Mar 14.
Abstract
Provided herein are novel tetrahydropyrido[3,4-]pyrimidines as HPK1 inhibitors, pharmaceutical compositions, use of such compounds in treating cancer, inflammatory, and autoimmune diseases, and processes for preparing such compounds.
摘要
本文提供了作为HPK1抑制剂的新型四氢吡啶并[3,4 -]嘧啶、药物组合物、此类化合物在治疗癌症、炎症和自身免疫性疾病中的用途，以及制备此类化合物的方法。
相似文献
1
Novel Tetrahydropyrido[3,4-]pyrimidines as HPK1 Inhibitors for Treating Cancer, Inflammatory, and Autoimmune Diseases.
ACS Med Chem Lett. 2024 Jan 31;15(3):318-319. doi: 10.1021/acsmedchemlett.4c00023. eCollection 2024 Mar 14.
2
Novel Pyrido[3,2-]pyrimidines as HPK1 Inhibitors for Treating Cancer and Inflammatory and Autoimmune Diseases.
ACS Med Chem Lett. 2023 Nov 27;14(12):1627-1628. doi: 10.1021/acsmedchemlett.3c00506. eCollection 2023 Dec 14.
3
Novel Diaminopyrimidine Carboxamides as HPK1 Inhibitors for Treating Cancer.
ACS Med Chem Lett. 2023 Jun 21;14(7):899-900. doi: 10.1021/acsmedchemlett.3c00249. eCollection 2023 Jul 13.
4
Design and synthesis of 1H-pyrazolo[3,4-d]pyrimidine derivatives as hematopoietic progenitor kinase 1 (HPK1) inhibitors.
Bioorg Chem. 2023 Nov;140:106811. doi: 10.1016/j.bioorg.2023.106811. Epub 2023 Aug 26.
5
Discovery of 7H-Pyrrolo[2,3-d]pyrimidine Derivatives as potent hematopoietic progenitor kinase 1 (HPK1) inhibitors.
Eur J Med Chem. 2023 Jun 5;254:115355. doi: 10.1016/j.ejmech.2023.115355. Epub 2023 Apr 10.
6
Novel Fused Triazole Compounds as RIPK1 Inhibitors for Treating Neurodegenerative, Autoimmune, and Inflammatory Diseases.
ACS Med Chem Lett. 2024 Jan 26;15(2):177-178. doi: 10.1021/acsmedchemlett.4c00011. eCollection 2024 Feb 8.
7
Novel Tyrosine Kinase 2 Inhibitors for Treating Autoimmune and Inflammatory Diseases.
ACS Med Chem Lett. 2024 May 16;15(6):769-770. doi: 10.1021/acsmedchemlett.4c00196. eCollection 2024 Jun 13.
8
TYK2 Inhibitors for Treating Autoimmune and Inflammatory Diseases.
ACS Med Chem Lett. 2024 Feb 6;15(3):320-321. doi: 10.1021/acsmedchemlett.4c00024. eCollection 2024 Mar 14.
9
Pyrrolidinone Derivatives as NIK Inhibitors for Treating Inflammatory and Autoimmune Diseases.
ACS Med Chem Lett. 2024 Feb 14;15(3):322-323. doi: 10.1021/acsmedchemlett.4c00044. eCollection 2024 Mar 14.
10
Pyrrolidinone Derivatives as NIK Inhibitors for Treating Autoimmune and Inflammatory Diseases.
ACS Med Chem Lett. 2024 Apr 23;15(5):581-582. doi: 10.1021/acsmedchemlett.4c00169. eCollection 2024 May 9.
本文引用的文献
1
Novel Pyrido[3,2-]pyrimidines as HPK1 Inhibitors for Treating Cancer and Inflammatory and Autoimmune Diseases.
ACS Med Chem Lett. 2023 Nov 27;14(12):1627-1628. doi: 10.1021/acsmedchemlett.3c00506. eCollection 2023 Dec 14.
2
PROTACs: Novel tools for improving immunotherapy in cancer.
Cancer Lett. 2023 Apr 28;560:216128. doi: 10.1016/j.canlet.2023.216128. Epub 2023 Mar 16.
3
Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death-ligand 1 inhibitors in non-small cell lung cancer.
Cancer. 2023 May 1;129(9):1319-1350. doi: 10.1002/cncr.34683. Epub 2023 Feb 27.
4
Role of protein phosphorylation in cell signaling, disease, and the intervention therapy.
MedComm (2020). 2022 Nov 3;3(4):e175. doi: 10.1002/mco2.175. eCollection 2022 Dec.
5
The development of small-molecule inhibitors targeting HPK1.
Eur J Med Chem. 2022 Dec 15;244:114819. doi: 10.1016/j.ejmech.2022.114819. Epub 2022 Oct 4.
Zotero 插件